Multimodal imaging in Alzheimer's disease: Validity and usefulness for early detection

The Lancet Neurology

Volumn 14, Issue 10, 2015, Pages 1037-1053

  Teipel, Stefan ^a,b   Drzezga, Alexander ^c   Grothe, Michel J ^a,b   Barthel, Henryk ^d   Chételat, Gaël ^f   Schuff, Norbert ^g   Skudlarski, Pawel ^h,i   Cavedo, Enrica ^j,k,r   Frisoni, Giovanni B ^j,l   Hoffmann, Wolfgang ^m,o   Thyrian, Jochen René ^n,o   Fox, Chris ^b   Minoshima, Satoshi ^p   Sabri, Osama ^e   Fellgiebel, Andreas ^q  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITÉ DE CAEN   (France)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h INSTITUTE OF LIVING   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^k SORBONNE UNIVERSITÉ   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m Neuroimaging Platform ^*  (France)

ⁿ UNIVERSITY OF GENEVA   (Switzerland)

^o UNIVERSITY OF GREIFSWALD   (Germany)

^p UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^q UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL PRACTICE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION TENSOR IMAGING; EARLY DIAGNOSIS; FRACTIONAL ANISOTROPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEALTH SERVICE; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIMODAL IMAGING; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; STANDARDS;

ALZHEIMER DISEASE; BIOMARKERS; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84942504717     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00093-9     Document Type: Review

References (142)

1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
3. New diagnostic criteria and guidelines for Alzheimer's disease Alzheimer's Association, (accessed July 24, 2015). http://www.alz.org/research/diagnostic_criteria/#use.
4. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015, 11:58-69.
5. Lleó A, Cavedo E, Parnetti L, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 2015, 11:41-55.
6. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
7. Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB Functional network disruption in the degenerative dementias. Lancet Neurol 2011, 10:829-843.
8. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52:1210-1217.
9. Vemuri P, Simon G, Kantarci K, et al. Antemortem differential diagnosis of dementia pathology using structural MRI: differential-STAND. Neuroimage 2011, 55:522-531.
10. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG-PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008, 49:390-398.
11. Hahn K, Myers N, Prigarin S, et al. Selectively and progressively disrupted structural connectivity of functional brain networks in Alzheimer's disease-revealed by a novel framework to analyze edge distributions of networks detecting disruptions with strong statistical evidence. Neuroimage 2013, 81:96-109.
12. Hastie T, Tibshirani R, Friedman J The elements of statistical learning-data mining inference, and prediction 2009, Springer, New York. 2nd edn.
13. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013, 9:e111-e194. the Alzheimer's Disease Neuroimaging Initiative.
14. Westman E, Simmons A, Muehlboeck JS, et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011, 58:818-828. the AddNeuroMed consortium, the Alzheimer's Disease Neuroimaging Initiativethe Alzheimer's Disease Neuroimaging Initiative.
15. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013, 40:104-114.
16. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC Tau imaging: early progress and future directions. Lancet Neurol 2015, 14:114-124.
17. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283. the AV45-A07 Study Group.
18. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760.
19. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014, 137:221-231. the AIBL Research Group.
20. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435. the Florbetaben Study Group.
21. Rowe C, Klunk W, Koeppe R, et al. The Centiloid Scale: standardization of amyloid imaging measures. Alzheimers Dement 2013, 9:8.
22. Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, et al. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 2012, 39:1042-1048.
23. Ikonomovic MD, Abrahamson EE, Price JC, et al. Early AD pathology in a [C-11]PIB negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012, 123:433-447.
24. Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011, 68:232-240.
25. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74:77-84.
26. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009, 66:1557-1562.
27. Villemagne VL, McLean CA, Reardon K, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009, 80:998-1001.
28. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
29. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007, 64:431-434.
30. Driscoll I, Troncoso JC, Rudow G, et al. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012, 124:823-831.
31. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011, 134:301-317.
32. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008, 65:1304-1309.
33. Serrano GE, Sabbagh MN, Sue LI, et al. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis 2014, 42:813-821.
34. Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement 2015, the Florbetaben Phase 3 Study Group, published online March 28. 10.1016/j.jalz.2015.02.004.
35. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015, 72:287-294.
36. Rinne JO, Wong DF, Wolk DA, et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012, 124:833-845.
37. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678. the AV-45-A16 Study Group.
38. Sabbagh MN, Fleisher A, Chen K, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Arch Neurol 2011, 68:1461-1466.
39. Jagust W, Reed B, Mungas D, Ellis W, Decarli C What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877.
40. Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Alzheimers Dement 2013, 9:e106-e109. the Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging.
41. Zhang S, Smailagic N, Hyde C, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014, 7. CD010386.
42. Ma Y, Zhang S, Li J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis [Corrected]. Medicine (Baltimore) 2014, 93:e150.
43. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63:2332-2340.
44. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005, 46:1625-1632.
45. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 753:230-238. the Alzheimer's Disease Neuroimaging Initiative.
46. Brück A, Virta JR, Koivunen J, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging 2013, 40:1567-1572.
47. Arbizu J, Prieto E, Martínez-Lage P, et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging 2013, 40:1394-1405. the Alzheimer's Disease Neuroimaging Initiative.
48. Korf ES, Wahlund LO, Visser PJ, Scheltens P Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004, 63:94-100.
49. Duara R, Loewenstein DA, Potter E, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 2008, 71:1986-1992.
50. Clerx L, van Rossum IA, Burns L, et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiol Aging 2013, 34:2003-2013.
51. Westman E, Cavallin L, Muehlboeck JS, et al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One 2011, 6:e22506. the AddNeuroMed consortium.
52. Bresciani L, Rossi R, Testa C, et al. Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetry. Aging Clin Exp Res 2005, 17:8-13.
53. Ridha BH, Barnes J, van de Pol LA, et al. Application of automated medial temporal lobe atrophy scale to Alzheimer disease. Arch Neurol 2007, 64:849-854.
54. Devanand DP, Liu X, Tabert MH, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 2008, 64:871-879.
55. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001, 22:747-754.
56. Ferrarini L, Frisoni GB, Pievani M, Reiber JH, Ganzola R, Milles J Morphological hippocampal markers for automated detection of Alzheimer's disease and mild cognitive impairment converters in magnetic resonance images. J Alzheimers Dis 2009, 17:643-659.
57. Devanand DP, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. Neuroimage 2012, 60:1622-1629.
58. Boutet C, Chupin M, Colliot O, et al. Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease?. Neuroradiology 2012, 54:1321-1330. the Alzheimer's Disease Neuroimaging Initiative.
59. Chupin M, Gérardin E, Cuingnet R, et al. Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 2009, 19:579-587. the Alzheimer's Disease Neuroimaging Initiative.
60. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012, 33:1203-1214. the North American Alzheimer's Disease Neuroimaging Initiative (ADNI).
61. Costafreda SG, Dinov ID, Tu Z, et al. Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage 2011, 56:212-219.
62. Dickerson BC, Wolk DA Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-betaβ and tau. Front Aging Neurosci 2013, 5:55. the Alzheimer's Disease Neuroimaging Initiative.
63. Leung KK, Barnes J, Ridgway GR, et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 2010, 51:1345-1359. the Alzheimer's Disease Neuroimaging Initiative.
64. Eskildsen SF, Coupé P, García-Lorenzo D, Fonov V, Pruessner JC, Collins DL Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage 2013, 65:511-521. the Alzheimer's Disease Neuroimaging Initiative.
65. Liu Y, Mattila J, Ruiz MA, et al. Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool. PLoS One 2013, 8:e55246. the Alzheimer's Disease Neuroimaging Initiative.
66. Wee CY, Yap PT, Shen D Prediction of Alzheimer's disease and mild cognitive impairment using cortical morphological patterns. Hum Brain Mapp 2013, 34:3411-3425. the Alzheimer's Disease Neuroimaging Initiative.
67. Aguilar C, Westman E, Muehlboeck JS, et al. Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res 2013, 212:89-98.
68. Lebedev AV, Westman E, Van Westen GJ, et al. Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. Neuroimage Clin 2014, 6:115-125. the Alzheimer's Disease Neuroimaging Initiative and the AddNeuroMed consortium.
69. Cho Y, Seong JK, Jeong Y, Shin SY Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data. Neuroimage 2012, 59:2217-2230. the Alzheimer's Disease Neuroimaging Initiative.
70. Gaser C, Franke K, Klöppel S, Koutsouleris N, Sauer H BrainAGE in mild cognitive impaired patients: predicting the conversion to Alzheimer's disease. PLoS One 2013, 8:e67346. the Alzheimer's Disease Neuroimaging Initiative.
71. Moradi E, Pepe A, Gaser C, Huttunen H, Tohka J Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects. Neuroimage 2015, 104:398-412. the Alzheimer's Disease Neuroimaging Initiative.
72. Mielke MM, Okonkwo OC, Oishi K, et al. Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. Alzheimers Dement 2012, 8:105-113.
73. Douaud G, Menke RA, Gass A, et al. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J Neurosci 2013, 33:2147-2155.
74. Selnes P, Aarsland D, Bjørnerud A, et al. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. J Alzheimers Dis 2013, 33:723-736.
75. Scola E, Bozzali M, Agosta F, et al. A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. J Neurol Neurosurg Psychiatry 2010, 81:798-805.
76. Fellgiebel A, Dellani PR, Greverus D, Scheurich A, Stoeter P, Müller MJ Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res 2006, 146:283-287.
77. Haller S, Nguyen D, Rodriguez C, et al. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis 2010, 22:315-327.
78. Bai F, Liao W, Watson DR, et al. Abnormal whole-brain functional connection in amnestic mild cognitive impairment patients. Behav Brain Res 2011, 216:666-672.
79. Petrella JR, Sheldon FC, Prince SE, Calhoun VD, Doraiswamy PM Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology 2011, 76:511-517.
80. Zhang D, Shen D Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012, 7:e33182. the Alzheimer's Disease Neuroimaging Initiative.
81. Yuan Y, Gu ZX, Wei WS Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol 2009, 30:404-410.
82. Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013, 266:583-591. the Alzheimer's Disease Neuroimaging Initiative.
83. Young J, Modat M, Cardoso MJ, Mendelson A, Cash D, Ourselin S Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neuroimage Clin 2013, 2:735-745. the Alzheimer's Disease Neuroimaging Initiative.
84. Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011, 56:52-60. the Alzheimer's Disease Neuroimaging Initiative.
85. 18F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. Neuroimage 2013, 64:517-525.
86. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
87. Hatashita S, Yamasaki H Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013, 8:e66877.
88. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract 2012, 66:185-198.
89. Trzepacz PT, Yu P, Sun J, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. Neurobiol Aging 2014, 35:143-151. the Alzheimer's Disease Neuroimaging Initiative.
90. Prestia A, Caroli A, Wade SK, et al. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement 2015, published online Jan 31. 10.1016/j.jalz.2014.12.001.
91. Joshi A, Koeppe RA, Fessler JA Reducing between scanner differences in multi-center PET studies. Neuroimage 2009, 46:154-159.
92. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995, 36:1238-1248.
93. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997, 42:85-94.
94. Magistretti PJ, Pellerin L The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry 1996, 1:445-452.
95. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
96. Yang L, Rieves D, Ganley C Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med 2012, 367:885-887.
97. Kril JJ, Hodges J, Halliday G Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neurosci Lett 2004, 361:9-12.
98. Freeman SH, Kandel R, Cruz L, et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 2008, 67:1205-1212.
99. Jack CR, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
100. Barnes J, Whitwell JL, Frost C, Josephs KA, Rossor M, Fox NC Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. Arch Neurol 2006, 63:1434-1439.
101. Klöppel S, Stonnington CM, Chu C, et al. Automatic classification of MR scans in Alzheimer's disease. Brain 2008, 131:681-689.
102. Tapiola T, Pennanen C, Tapiola M, et al. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol Aging 2008, 29:31-38.
103. Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
104. Misra C, Fan Y, Davatzikos C Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009, 44:1415-1422.
105. Fox C, Lafortune L, Boustani M, Dening T, Rait G, Brayne C Screening for dementia-is it a no brainer?. Int J Clin Pract 2013, 67:1076-1080.
106. Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008, 70:191-199.
107. Delbeuck X, Van der Linden M, Collette F Alzheimer's disease as a disconnection syndrome?. Neuropsychol Rev 2003, 13:79-92.
108. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 2003, 20:1714-1722.
109. Teipel SJ, Reuter S, Stieltjes B, et al. Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study. Psychiatry Res 2011, 194:363-371.
110. Biswal BB, Mennes M, Zuo XN, et al. Toward discovery science of human brain function. Proc Natl Acad Sci USA 2010, 107:4734-4739.
111. Jiang X, Zhang X, Zhu D Intrinsic functional component analysis via sparse representation on Alzheimer's disease neuroimaging initiative database. Brain Connect 2014, 4:575-586.
112. Thomas JB, Brier MR, Bateman RJ, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol 2014, 71:1111-1122.
113. Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008, 131:3286-3298.
114. Keller CJ, Bickel S, Honey CJ, et al. Neurophysiological investigation of spontaneous correlated and anticorrelated fluctuations of the BOLD signal. J Neurosci 2013, 33:6333-6342.
115. Clerx L, Visser PJ, Verhey F, Aalten P New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 2012, 29:405-429.
116. Brüggen K, Dyrba M, Barkhof F, et al. Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: a multicenter DTI and volumetry study. J Alzheimers Dis 2015, 10.3233/JAD-150063.
117. Barkhof F, Haller S, Rombouts SA Resting-state functional MR imaging: a new window to the brain. Radiology 2014, 272:29-49.
118. Bellman R Adaptive control processes. A guided tour 1961, Princeton University Press, Princeton.
119. James GA, Witten D, Hastie T, Tibshirani R An introduction to statistical learning with applications in R 2013, Springer, New York.
120. McMillan CT, Avants BB, Cook P, Ungar L, Trojanowski JQ, Grossman M The power of neuroimaging biomarkers for screening frontotemporal dementia. Hum Brain Mapp 2014, 35:4827-4840.
121. Zou H, Hastie T Regularization and variable selection via the elastic net. J R Stat Soc B 2005, 67:301-320.
122. Teipel SJ, Kurth J, Krause B, Grothe MJ The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment-beyond classical regression. Neuroimage Clin 2015, published online May 21. 10.1016/j.nicl.2015.05.006.
123. Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2013, 2:356-365.
124. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475.
125. Förster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012, 71:792-797.
126. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
127. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
128. Knopman DS, Jack CR, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 2013, 73:472-480.
129. Chételat G Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nat Rev Neurol 2013, 9:123-124.
130. Frisoni GB, Bocchetta M, Chételat G, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013, 81:487-500. the ISTAART's NeuroImaging Professional Interest Area.
131. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804. the Dominantly Inherited Alzheimer Network.
132. Bouwman FH, Verwey NA, Klein M, et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010, 30:1-7.
133. Galluzzi S, Geroldi C, Ghidoni R, et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010, 257:2004-2014. the Translational Outpatient Memory Clinic Working Group.
134. Ossenkoppele R, Prins ND, Pijnenburg YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013, 9:414-421.
135. Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol 2009, 9:41.
136. Kaduszkiewicz H, Zimmermann T, Van den Bussche H, et al. Do general practitioners recognize mild cognitive impairment in their patients?. J Nutr Health Aging 2010, 14:697-702. the AgeCoDe Study Group.
137. Eichler T, Thyrian JR, Hertel J, et al. Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial. J Alzheimers Dis 2014, 42:451-458.
138. Boustani M, Callahan CM, Unverzagt FW, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 2005, 20:572-577.
139. Bringing forward the diagnosis of Alzheimer's disease. Lancet Neurol 2014, 13:961. The Lancet Neurology.
140. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
141. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013, 27:4-15. the 45-A17 Study Group.
142. Thyrian JR, Fiß T, Dreier A, et al. Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials 2012, 13:56.